Graeme Young

Graeme Young

Auto-generated profile, based on publicly available information

Graeme Young

Bioanalysis, Immunogenicity and Biomarkers (BIB), GSK, Ware, Hertfordshire, UK

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 September 2020 in Nature Reviews Drug Discovery
Verified
Journal Article
Closed access
PDF file
TBTal Burt
Tal Burt
GYGraeme Young
Graeme Young
WLWooin Lee
Wooin Lee
HKHiroyuki Kusuhara
Hiroyuki Kusuhara
OLOliver Langer
Oliver Langer
YSYuichi Sugiyama
Yuichi Sugiyama

26 September 2011 in Bioanalysis
Verified
Journal Article
Closed access
FGFabio Garofolo
Fabio Garofolo
MRMario L Rocci
Mario L Rocci
IDIsabelle Dumont
Isabelle Dumont
SMSuzanne Martinez
Suzanne Martinez
SLSteve Lowes
Steve Lowes
GYGraeme Young
Graeme Young
The 5th Workshop on Recent Issues in Bioanalysis (WRIB) was organized by the Calibration and Validation Group as a 2-day full immersion workshop for pharmaceutical companies, CROs and regulatory agencies to discuss, review, share perspectives, provide potential solutions and agree upon a consistent approach to recent issues in the bioanalysis of both small and large molecules. High quality, better compliance to regulations and scientific excellence are the foundation of this workshop. As in the previous editions of this significant event, recommendations were made and a consensus was reached among panelists and attendees, including industry leaders and regulatory experts representing the global bioanalytical community, on many 'hot' topics in bioanalysis. This 2011 White Paper is based on the conclusions from this workshop, and aims to provide a practical reference guide on those topics.

12 December 2000 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Closed access
RGR.C Garner
R.C Garner
James BarkerJames Barker
James Barker
CFC Flavell
C Flavell
JGJ.V Garner
J.V Garner
MWM Whattam
M Whattam
DLD Leong
D Leong

20 November 2014 in British Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
CBClaire Beaumont
Claire Beaumont
GYGraeme C. Young
Graeme C. Young
TCTom Cavalier
Tom Cavalier
MYMalcolm A. Young
Malcolm A. Young

1 January 2001 in Xenobiotica
Verified
Journal Article
Closed access
GYG. Young
G. Young
WEW. Ellis
W. Ellis
JAJ. Ayrton
J. Ayrton
EHE. Hussey
E. Hussey
BAB. Adamkiewicz
B. Adamkiewicz
1. The technique of accelerator mass spectrometry (AMS) is outlined. 2. The use of AMS in an initial validation study in animals is outlined. As part of the validation of the technique, samples from the animal study were analysed by both liquid scintillation counting (LSC) and, following dilution, by AMS. The results were similar. 3. The use of AMS in support of a clinical study is described. Six healthy male human volunteers were administered 2.7mg [14

1 January 2013 in Drug Metabolism and Disposition
Verified
Journal Article
Closed access
AHAndrew W Harrell
Andrew W Harrell
SSSarah K Siederer
Sarah K Siederer
JBJo Bal
Jo Bal
NPNainesh H Patel
Nainesh H Patel
GYGraeme C Young
Graeme C Young
RKRodger D Kempsford
Rodger D Kempsford
The metabolism and disposition of vilanterol, a novel long-acting β(2)-adrenoceptor agonist (LABA) for inhalation use, was investigated after oral administration in humans. Single oral administrations of up to 500 μg of vilanterol were shown to be safe and well tolerated in two clinical studies in healthy men. In a human radiolabel study, six healthy men received a single oral dose of 200 μg of [(14)C]vilanterol (74 kBq). Plasma, urine, and feces were collected up to 168 hours after the dose and were analyzed for vilanterol, metabolites, and radioactivity. At least 50% of the radioactive dose was orally absorbed. The primary route of excretion of drug-related material was via O-dealkylation to metabolites, which were mainly excreted in urine. Vilanterol represented a very small percentage (<0.5%) of the total drug-related material in plasma, indicative of extensive first-pass metabolism. Circulating metabolites resulted mainly from O-dealkylation and exhibited negligible pharmacologic activity. The therapeutic dose level for vilanterol is 25 μg by the inhalation route. At this low-dose level, the likelihood of pharmacologically inactive metabolites causing unexpected toxicity is negligible. In addition to providing an assessment of the disposition of vilanterol in human, this work highlights a number of complexities associated with determining human absorption, distribution, metabolism, and excretion (ADME) for inhaled molecules--mainly related to the low chemical doses and complications associated with the inhalation route of administration.